ECOG 4599: first-line Avastin-based therapy – the first combination to achieve OS beyond the historical benchmark of 1 year
Avastin-based therapy extends survival beyond conventional paclitaxel/carboplatin chemotherapy, with OS >1 year
ECOG 4599: OS5
Copyright ©2006 Massachusetts Medical Society. All rights reserved.
- In ECOG 4599, the addition of a platinum doublet to Avastin significantly increased OS, PFS and ORR in the overall non-squamous NSCLC population versus chemotherapy alone.5
- Median OS increased from 10.3 to 12.3 months with Avastin-based therapy (HR=0.79).5
- Disclaimer: Avastin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.avastin.comThe information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.